{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-009988","form_type":"8-K","ticker":"TENX","cik":"0000034956","company_name":"TENAX THERAPEUTICS, INC.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.500592+00:00","generated_at":"2026-05-31T12:44:31.012411+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Tenax Therapeutics Raises $100M in Oversubscribed Private Placement Led by BVF Partners","bullets":["Gross proceeds ~$100M from 1.45M shares, 31.9M pre-funded warrants, and 16.7M warrants at $3.00/share (warrant strike $4.50).","Private placement led by BVF Partners LP; new investors include Venrock, Vivo Capital, Janus Henderson, Vestal Point, Velan Capital, ADAR1, Stonepine, Sphera Biotech.","Net proceeds to complete Phase 3 LEVEL trial and initiate second Phase 3 trial of oral levosimendan; cash runway extended through end of 2027.","Expected to close August 8, 2024; Leerink Partners lead placement agent, with Guggenheim, William Blair as joint agents; ROTH Capital financial advisor.","Post-closing common shares outstanding expected to be approximately 3.4 million."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-009988","json":"https://secwatch.observer/filing/0001654954-24-009988.json","markdown":"https://secwatch.observer/filing/0001654954-24-009988.md","text":"https://secwatch.observer/filing/0001654954-24-009988.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/0001654954-24-009988-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/34956/000165495424009988/tenx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:44:31.012411+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}